(Q37994088)

26 August 2017

How to manage acute promyelocytic leukemia (English)

1 reference

26 August 2017

1 reference

J-Q Mi

1

1 reference

26 August 2017

J-M Li

2

1 reference

26 August 2017

Z-X Shen

3

1 reference

26 August 2017

S-J Chen

4

1 reference

26 August 2017

Z Chen

5

1 reference

26 August 2017

16 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

26

1 reference

26 August 2017

8

1 reference

26 August 2017

1743-1751

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.57

26 August 2017

0 references

cites work

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

How I treat acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Identification of the constant chromosome regions involved in human hematologic malignant disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

RXR is an essential component of the oncogenic PML/RARA complex in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Recruitment of RXR by Homotetrameric RARα Fusion Proteins Is Essential for Transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Stem cell regulation by polycomb repressors: postponing commitment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

PML targeting eradicates quiescent leukaemia-initiating cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Modern approaches to treating acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

A systematic overview of chemotherapy effects in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Retinoic acid and arsenic for treating acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Prolongation of cardiac repolarization by arsenic trioxide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.57

7 January 2021

Identifiers

DOI

10.1038/LEU.2012.57

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference